Research Article

A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients

Table 2

Sociodemographic and general health characteristics.

Patient characteristics   Frequency (percentage) or
mean (range)
Viscum   Etoposide  

Gender
 Male4 (44.4) 7 (63.6)
 Female5 (55.6) 4 (39.4)
Age (years) 28 (18–48) 39 (11–66)
Ethnic group
 Caucasian8 (88.9)11 (100)
 Asian1 (11.1)
Family status
 Single/divorced8 (88.9) 6 (54.5)
 Married/in partnership1 (11.1)5 (45.5)
Highest education
 Vocational training5 (55.6) 7 (63.6)
 University graduate/student 4 (44.4) 4 (36.5)
ECOG
 03 (33.3)6 (54.6)
 16 (66.7)5 (45.4)
 ≥2
Concomitant diseases 1 (11.1)3 (27.3)
 Paget syndrome1 (11.1)
 HCV1 (11.1)
 Primary hyperparathyroidism1 (11.1)
 Kidney tubulopathy1 (11.1)
Current regular medication5 (55.6) 6 (54.6)
Current signs and symptoms
 Pain 2 (22.2)1 (9.1)
 Weight loss2 (22.2)1 (9.1)
 Cough1 (11.1)1 (9.1)
 Dyspnea1 (11.1)